Lung Cancer Clinical Trials in Créteil
23 recruitingCréteil, France
Showing 1–20 of 23 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2Phase 3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE1,260 enrolled184 locationsNCT06712316
Recruiting
Phase 2
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
BicycleTx Limited73 enrolled29 locationsNCT06933329
Recruiting
Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Daiichi Sankyo540 enrolled230 locationsNCT06203210
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-small Cell Lung Cancer
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Non-small Cell Lung Cancer
AstraZeneca180 enrolled77 locationsNCT06448754
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca300 enrolled40 locationsNCT06726720
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled244 locationsNCT05899608
Recruiting
Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non Small Cell Lung Cancer
NovoCure GmbH734 enrolled90 locationsNCT06216301
Recruiting
Phase 3
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Advanced Non-Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique133 enrolled29 locationsNCT06908993
Recruiting
Phase 4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
Lung CancerNon-small Cell Lung Cancer
GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancer
GFPC Investigation1,000 enrolled46 locationsNCT07243132
Recruiting
Phase 2
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Metastatic Lung CancerAdvanced NSCLC
Mirati Therapeutics Inc.90 enrolled166 locationsNCT05609578
Recruiting
Not Applicable
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Not Applicable
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie30 enrolled18 locationsNCT06247826
Recruiting
Phase 3
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Triple-Negative Breast CancerCervical CancerUrothelial Carcinoma+12 more
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Lung Cancer
UNICANCER70,000 enrolled21 locationsNCT03848052